===Zevra Therapeutics (ZVRA) announces organizational changes

 

• Co announces organizational changes designed to accelerate its transformation into a leading rare disease therapeutics company. Co is consolidating its development and scientific functions under Adrian Quartel, M.D., FFPM, Chief Medical Officer. Adrian will be responsible for clinical development, quality assurance, and regulatory and scientific affairs. As part of these changes, Christal M.M. Mickle, Chief Development Officer, and Sven Guenther, Ph.D., Chief Scientific Officer, are departing Zevra effective December 6, 2024, and December 23, 2024, respectively.
• Co has also eliminated positions in chemistry, manufacturing and controls and Clinical Development, consistent with the change in portfolio priorities.

===Interpublic Group (IPG) to be acquired by Omnicom (OMC) in all-stock deal

 

Omnicom to acquire Interpublic Group in all-stock deal

• Omnicom (OMC) and The Interpublic Group of Companies (IPG) have unanimously approved a definitive agreement pursuant to which Omnicom will acquire Interpublic in a stock-for-stock transaction.
• Interpublic shareholders will receive 0.344 Omnicom shares for each share of Interpublic common stock they own.
• Following the close of the transaction, Omnicom shareholders will own 60.6% of the combined company and Interpublic shareholders will own 39.4%, on a fully diluted basis. The transaction is expected to generate annual cost synergies of $750 mln.
• The new Omnicom will have over 100,000 expert practitioners. The company will deliver end-to-end services across media, precision marketing, CRM, data, digital commerce, advertising, healthcare, public relations and branding.

===Protara Therapeutics (TARA) : Positive results from Phase 2 ADVANCED-2 trial of TARA-002 in patients with NMIBC

• TARA-002 demonstrates 72% six-month landmark complete response rate and 70% complete response rate at any time across BCG exposures
• 100% six-month landmark complete response rate and 80% complete response rate at any time observed in BCG-Unresponsive patients
• 64% six-month landmark complete response rate and 67% complete response rate at any time observed in BCG-Naïve patients
• 80% reinduction salvage rate and compelling durability observed with 100% of patients maintaining a complete response from three months to six months across BCG exposures
• Favorable safety and tolerability profile with no Grade 2 or greater treatment-related adverse events

 

Company Profile

• Protara Therapeutics
• Industry: Health Care
• Website: https://artaratx.com/

=-=Pure Storage (PSTG) reported earnings on Tue 3 Dec 24 (a/h)

 

 Pure Storage beats by $0.09, beats on revs; guides Q4 revs above consensus 

• Reports Q3 (Oct) earnings of $0.50 per share, excluding non-recurring items, $0.09 better than the FactSet Consensus of $0.41; revenues rose 9.0% year/year to $831.1 mln vs the $814.9 mln FactSet Consensus.
• Subscription annual recurring revenue (ARR) $1.6 billion, up 22% year-over-year.
• Remaining performance obligations (RPO) $2.4 billion, up 16% year-over-year.
• Co issues upside guidance for Q4, sees Q4 revs of $867 mln vs. $855.87 mln FactSet Consensus. Sees Non-GAAP Operating Margin of 15.6%.